Health Care & Life Sciences » Biotechnology | Catabasis Pharmaceuticals Inc.

Catabasis Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
-
-
-
500.00
119
Cost of Goods Sold (COGS) incl. D&A
320.00
248.00
202.00
395.00
-
119
Gross Income
320.00
248.00
202.00
395.00
-
119
SG&A Expense
17,799.00
21,433.00
31,457.00
35,163.00
27,290.00
25,352
EBIT
18,119.00
21,681.00
-
35,558.00
27,094.00
25,471
Non Operating Income/Expense
1.00
3.00
7.00
93.00
32.00
176
Interest Expense
-
206.00
978.00
837.00
462.00
100
Pretax Income
18,118.00
21,884.00
32,630.00
36,060.00
27,364.00
25,870
Consolidated Net Income
18,118.00
21,884.00
32,630.00
36,060.00
27,364.00
25,870
Net Income
18,118.00
21,884.00
32,630.00
36,060.00
27,364.00
25,870
Net Income After Extraordinaries
18,118.00
21,884.00
32,630.00
36,060.00
27,364.00
25,870
Net Income Available to Common
18,118.00
21,884.00
32,630.00
36,060.00
27,364.00
25,870
EPS (Basic)
1.18
1.43
4.06
2.22
1.26
5.12
Basic Shares Outstanding
15,297.80
15,297.80
8,041.90
16,230.20
21,681.50
5,054.80
EPS (Diluted)
1.18
1.43
4.06
2.22
1.26
5.12
Diluted Shares Outstanding
15,297.80
15,297.80
8,041.90
16,230.20
21,681.50
5,054.80
EBITDA
17,799.00
21,433.00
31,457.00
35,163.00
26,790.00
25,352
Non-Operating Interest Income
-
-
-
242.00
160.00
425

About Catabasis Pharmaceuticals

View Profile
Address
One Kendall Square
Cambridge Massachusetts 02139
United States
Employees -
Website http://www.catabasis.com
Updated 07/08/2019
Catabasis Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery, development, and commercialization of therapeutics for the treatment of cardiovascular, metabolic and inflammatory diseases. The company was founded by Jill C.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.